BrainCool (BRAIN.ST)

Executive Summary

BrainCool Inc., a subsidiary of BrainCool AB (publ), is a medical device company specializing in innovative temperature management solutions. Its flagship product, the IQool™ System, provides precise and easy-to-use temperature control for clinical applications such as post-cardiac arrest care, stroke, and other neurological conditions. The system is designed to improve patient outcomes by rapidly inducing and maintaining therapeutic hypothermia or normothermia. With a presence in the United States and a listing on the Stockholm Stock Exchange (BRAIN.ST), BrainCool has a market valuation of approximately $298 million. The company focuses on addressing unmet needs in critical care and neurology, leveraging its proprietary technology to offer a non-invasive, cost-effective alternative to existing cooling methods. BrainCool's commercial-stage status and single-product focus position it for growth through expanded indications and geographic penetration.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for expanded indication in stroke or cardiac arrest70% success
• Q2 2026Strategic partnership or distribution agreement with a major hospital network or medical device company60% success
• TBDPositive clinical trial results or publication supporting IQool System efficacy50% success